STOK Stoke Therapeutics Inc

Price (delayed)

$26.11

Market cap

$1.68B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.37

Enterprise value

$1.57B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 21
Highlights
Stoke Therapeutics's quick ratio has decreased by 16% from the previous quarter but it has increased by 12% YoY
Stoke Therapeutics's equity has decreased by 12% from the previous quarter but it has increased by 3.2% YoY
The company's gross profit has shrunk by 86% YoY and by 14% QoQ
The revenue has plunged by 86% YoY and by 14% from the previous quarter

Key stats

What are the main financial stats of STOK

STOK stock price

How has the Stoke Therapeutics stock price performed over time
Intraday
-10.58%
1 week
-6.45%
1 month
-19.14%
1 year
15.38%
YTD
-17.74%
QTD
-20.2%

Financial performance

How have Stoke Therapeutics's revenue and profit performed over time
Revenue
$27.59M
Gross profit
$27.59M
Operating income
-$223.38M
Net income
-$207.9M
Gross margin
100%
Net margin
-753.6%
The company's gross profit has shrunk by 86% YoY and by 14% QoQ
The revenue has plunged by 86% YoY and by 14% from the previous quarter
STOK's net margin is down by 42% since the previous quarter
The operating margin has contracted by 40% from the previous quarter

Price vs fundamentals

How does STOK's price correlate with its fundamentals

Growth

What is Stoke Therapeutics's growth rate over time

Valuation

What is Stoke Therapeutics stock price valuation
P/E
N/A
P/B
4.71
P/S
62.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
57.08
The EPS has contracted by 19% from the previous quarter
The P/B is 75% above the 5-year quarterly average of 3.0 and 5% above the last 4 quarters average of 5.0
Stoke Therapeutics's equity has decreased by 12% from the previous quarter but it has increased by 3.2% YoY
The revenue has plunged by 86% YoY and by 14% from the previous quarter
The price to sales (P/S) is 76% higher than the last 4 quarters average of 39.8 and 39% higher than the 5-year quarterly average of 50.2

Efficiency

How efficient is Stoke Therapeutics business performance
The ROS has contracted by 40% from the previous quarter
The ROE has declined by 22% since the previous quarter
STOK's ROA is down by 22% from the previous quarter
STOK's return on invested capital is down by 21% since the previous quarter

Dividends

What is STOK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for STOK.

Financial health

How did Stoke Therapeutics financials performed over time
Stoke Therapeutics's quick ratio has decreased by 16% from the previous quarter but it has increased by 12% YoY
STOK's current ratio is down by 14% since the previous quarter but it is up by 10% year-on-year
STOK's debt is 100% smaller than its equity
Stoke Therapeutics's equity has decreased by 12% from the previous quarter but it has increased by 3.2% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.